BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 5, 2010
View Archived Issues
GTx Mum as Merck Discontinues Phase II SARM Ostarine/MK-2866
Four months after GTx Inc. suffered a devastating FDA setback with lead program toremifene, the biotech's second program - Phase II muscle loss drug Ostarine/MK-2866 - has been discontinued by partner Merck and Co. Inc. (BioWorld Today)
Read More
Senators Agree on Language in Long-Debated Patent Reform
Read More
News Times Three: SpePharm Adds Product, Partner, Money
Read More
Vaxart Raises $12.5M in Series B to Take Oral Vaccine into Clinic
Read More
Columbia Labs Getting $92.5M in Watson Progesterone Deal
Read More
Other News To Note
Read More
Clinic Roundup
Read More
U.S. Patent Disclosures
Read More